Reserved for patients who fail to respond to NSAIDs or who have severe or rapidly progressive disease, these pharmacologically diverse drugs have no common mode of action. Half of rheumatoid arthritis patients will ultimately need such therapy, and for them, finding a drug that is effective and can be tolerated may in some cases require trials of four or more drugs.